Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2017

View Archived Issues

Frequency Therapeutics announces closing of series A financing

Inovio Pharmaceuticals reports initial results from phase I study of Ebola vaccine

Appili Therapeutics receives funding from Canadian government to develop antibiotic

FDA grants reactivation status for MARVEL phase II/III trial

Preclinical characterization of the novel adenosine A2A receptor inhibitor AZD-4635

LTT Bio-Pharma reports results of phase II clinical trial for LT-4002

Positive topline results from phase II trial of SB-208

Janssen develops promising tau PET tracer JNJ-067

First patient treated in METROmaJX study of Pexa-Vec

New Alzheimer's disease model uses hearing impairment to assess progression

BioCryst Pharmaceuticals announces plans to test oral liquid formulation of BCX-7353

KNOW Bio Respiratory changes name to Novoclem Therapeutics

Ironshore announces plans for two pivotal studies of HLD-100

First clinical study of gastrin analogue CP-04 as a theranostic for medullary thyroid carcinoma

XOMA tests anti-PTH1R human monoclonal antibodies in vitro and in rodent models

Positive phase III 6-month topline safety and efficacy results from Rocket-4 study of Rhopressa

Araxes Pharma discloses novel RAS family inhibitors

Siemens Healthineers receives HSS funding for the development of novel Zika diagnostic test

Taisho Pharmaceutical patents orexin receptor antagonists

Novel MALT1 inhibitors identified at Toray Industries

Roche launches diagnostic antibody to help distinguish morphologically difficult prostate cancers

Concert Pharmaceuticals discovers new CFTR potentiators

Sichuan Haisco Pharmaceutical discloses new muscarinic receptor antagonists

Jagiellonian University and collaborators patent 5-HT6 receptor antagonists

Shionogi applies for manufacture and sales approval for lisdexamfetamine dimesylate in Japan

GlaxoSmithKline initiates first-in-human trial of GSK-3036656

Patient enrollment begins in phase III AURORA trial of cenicriviroc

Mayo Clinic initiates phase I trial of VSV-hIFNbeta-NIS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...